002C-3通过抑制MMPs和细胞自噬并激活细胞存活相关的钙信号通路保护小鼠脑缺血再灌注损伤

doi:10.5246/jcps.2016.08.067

中国药学(英文版) ›› 2016, Vol. 25 ›› Issue (8): 598-604.DOI: 10.5246/jcps.2016.08.067

002C-3通过抑制MMPs和细胞自噬并激活细胞存活相关的钙信号通路保护小鼠脑缺血再灌注损伤

张精亮^1#, 胡涛^1#, 刘晓岩¹, 朱元军¹, 陈晓玲¹, 刘晔², 王银叶^1*

1. 北京大学医学部药学院分子与细胞药理学系, 北京 100191
2. 北京红惠新药科技有限公司, 北京 102600

收稿日期:2016-02-27 修回日期:2016-04-15 出版日期:2016-09-01 发布日期:2016-05-10
通讯作者: Tel.: +86-010-82802652/+86-010-62015584, E-mail: wangyinye@bjmu.edu.cn
基金资助:
National Natural Science Foundation of China (Grant No. 81302763, 81573333) and Beijing Natural Science Foundation (Grant No. 7144218).

002C-3 protects the brain against ischemia-reperfusion injury by inhibiting autophagy and stimulating CaMKK/CaMKIV/HDAC4 pathways in mice

Jingliang Zhang^1#,Tao Hu^1#, Xiaoyan Liu¹, Yuanjun Zhu¹, Xiaoling Chen¹, Ye Liu², Yinye Wang^1*

1. Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
2. Beijing Honghui New Medical Technology Co.Ltd., Beijing Daxing Biological Medicine Industry Base, Beijing 102600,China

Received:2016-02-27 Revised:2016-04-15 Online:2016-09-01 Published:2016-05-10
Contact: Tel.: +86-010-82802652/+86-010-62015584, E-mail: wangyinye@bjmu.edu.cn
Supported by:
National Natural Science Foundation of China (Grant No. 81302763, 81573333) and Beijing Natural Science Foundation (Grant No. 7144218).

摘要/Abstract

摘要：

研究厚朴酚衍生物002C-3对小鼠中脑动脉缺血(MCAO)再灌注损伤的作用及可能的机制。与模型对照组相比, 在缺血1.5 h后单次静注002C-3 (100和150 μg/kg)可明显减小神经缺陷评分, 缩小脑梗死体积和降低脑水含量。002C-3 (75-150 µg/kg)可明显减少脑毛细血管伊文氏蓝的渗出量。与模型对照组相比, 002C-3 (100 μg/kg)可明显抑制缺血半脑组织中的基质金属蛋白酶MMP-9和MMP-2的活性; 减少自噬相关蛋白Beclin-1和LC3B-II的表达, 增加p-62蛋白的表达; 002C-3还可增加细胞存活相关的钙信号蛋白p-CaMKIV和p-HDAC4的表达。这些结果表明: 002C-3在小鼠脑缺血再灌注损伤模型上有明显的神经保护作用, 其作用机制可能与抑制MMPs活性, 保护血脑屏障, 抑制缺血诱导的细胞自噬以及激活细胞存活相关的钙信号通路有关。

关键词: 002C-3, 脑缺血再灌注, 脑微血管通透性, 自噬, CaMKK/CaMKIV/HDAC4通路

Abstract:

This study was designed to investigate the effect of 002C-3, a derivative of magnolol, on transient cerebral middle occlusion (tMCAO) in a mice model and to identify the underlying mechanisms. 002C-3 (100 and 150 μg/kg, i.v. after ending occlusion) significantly reduced neurological deficit scores, infarct volumes, and brain water contents after 1.5 h MCAO and 24 h reperfusion. 002C-3 (75-150 µg/kg) decreased the exudation of Evans blue from brain capillaries. 002C-3 (100 μg/kg) significantly inhibited the activity of MMP-9 and MMP-2 in the injured hemisphere. 002C-3 decreased the expression of autophagy-associated proteins, Beclin-1 and LC3B-II, and increased the level of p62 in injured hemisphere. 002C-3 (100 μg/kg) significantly increased the expression of p-CaMKIV and p-HDAC4 in injured hemisphere. In conclusion, 002C-3 shows a neuroprotective effect on tMCAO injury in mice, and its mechanisms may be associated with alleviation of blood-brain barrier damage caused by the activation of MMPs, inhibition of autophagy, and stimulation of calcium signals related to cell survival. These findings suggest that 002C-3 is a neuroprotective agent that acts on multiple pathways.

Key words: 002C-3, Cerebral ischemia-reperfusion, Microvascular permeability, Autophagy, CaMKK/CaMKIV/HDAC4 pathway

中图分类号:

R962

Supporting:

张精亮, 胡涛, 刘晓岩, 朱元军, 陈晓玲, 刘晔, 王银叶. 002C-3通过抑制MMPs和细胞自噬并激活细胞存活相关的钙信号通路保护小鼠脑缺血再灌注损伤[J]. 中国药学(英文版), 2016, 25(8): 598-604.

Jingliang Zhang, Tao Hu, Xiaoyan Liu, Yuanjun Zhu, Xiaoling Chen, Ye Liu, Yinye Wang. 002C-3 protects the brain against ischemia-reperfusion injury by inhibiting autophagy and stimulating CaMKK/CaMKIV/HDAC4 pathways in mice[J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(8): 598-604.

参考文献

[1] Turner, R.C.; Dodson, S.C.; Rosen, C.L.; Huber, J.D. J. Neurosurg. 2013, 118, 1072-1085.
[2] Fisher, M.; Feuerstein, G.; Howells, D.W.; Hurn, P.D.; Kent, T.A.; Savitz, S.I.; Lo, E.H. Stroke. 2009, 40, 2244-2250.
[3] Lo, E.H.; Dalkara, T.; Moskowitz, M.A. Nat. Rev. Neurosci. 2003, 4, 399-415.
[4] Lee, W.T.; Lin, M.H.; Lee, E.J.; Hung, Y.C.; Tai, S.H.; Chen, H.Y.; Chen, T.Y.; Wu, T.S. PloS One. 2012, 7, e39952.
[5] Chen, Y.H.; Huang, P.H.; Lin, F.Y.; Chen, W.C.; Chen, Y.L.; Yin, W.H.; Man, K.M.; Liu, P.L. Eur. J. Integ. Med. 2011, 3, e317-e324.
[6] Liang, C.J.; Lee, C.W.; Sung, H.C.; Chen, Y.H.; Wang, S.H.; Wu, P.J.; Chiang, Y.C.; Tsai, J.S.; Wu, C.C.; Li, C.Y.; Chen, Y.L. Am. J. Chin. Med. 2014, 42, 619-637.
[7] Huang, X.; Wang, C.; Chen, K.; Xiang, T.; Han, Z. Chin. J. Neuroimmunol. Neurol. 2007, 14, 118-119.
[8] Lin, Y.R.; Chen, H.H.; Ko, C.H.; Chan, M.H. Eur. J. Pharmacol. 2006, 537, 64-69.
[9] Pyo, M.K.; Lee, Y.; Yun-Choi, H.S. Arch. Pharmacol. Res. 2002, 25, 325-328.
[10] Yan, Y.; Lin, Q.; Xu, Y.; Huang, X. Chin. J. Exp. Tradit. Med. Formul. 2011, 17, 223-225.
[11] Li, H.; Liu, X.; Zhu, Y.; Liu, Y.; Wang, Y. Neurosci. Lett. 2015, 588, 178-183.
[12] Chiang, T.; Messing, R.O.; Chou, W.H. J. Visual. Exp. 2011. JoVE (48).
[13] Liu, F.; McCullough, L.D. Methods Mol. Biol. 2014, 1135, 81-93.
[14] Rousselet, E.; Kriz, J.; Seidah, N.G. J. Visual. Exp. 2012, JoVE(69).
[15] Chao, X.; Zhou, J.; Chen, T.; Liu, W.; Dong, W.; Qu, Y.; Jiang, X.; Ji, X.; Zhen, H.; Fei, Z. Brain Res. 2010, 1363, 206-211.
[16] Cevik, N.G.; Orhan, N.; Yilmaz, C.U.; Arican, N.; Ahishali, B.; Kucuk, M.; Kaya, M.; Toklu, A.S. Brain Res. 2013, 1531, 113-121.
[17] Toth, M.; Sohail, A.; Fridman, R. In Metastasis Research Protocols, 2012, Springer. 121-135.
[18] McCullough, L.D.; Tarabishy, S.; Liu, L.; Benashski, S.; Xu, Y.; Ribar, T.; Means, A.; Li, J. Stroke. 2013. 44, 2559-2566.
[19] Bolger, T.A.; Yao, T.P. J. Neurosci: the official journal of the Society for Neuroscience. 2005, 25, 9544-9553.
[20] Liu, Y.; Liu, K.; Liu, J.; Li, J. Chin. J. Gerontol. 2014, 1, 135.
[21] Xu, F.; Gu, J.; Qin, Z. Neurosci. Bullet. 2012, 28, 658-666.
[22] Carloni, S.; Buonocore, G.; Balduini, W. Neurobiol Dis. 2008, 32, 329-339.
[23] Zheng, Y.; Liu, J.; Li, X.; Xu, L.; Xu, Y. Acta Pharmacol. Sin. 2009, 30, 919-927.
[24] Wang, J.; Xia, Q.; Chu, K.; Pan, J.; Sun, L.; Zeng, B.; Zhu, Y.; Wang, Q.; Wang, K.; Luo, B. J. Neuropathol. Exp. Neurol. 2011, 70, 314-322.
[25] Zhang, X.; Yan, H.; Yuan, Y.; Gao, J.; Shen, Z.; Cheng, Y.; Shen, Y.; Wang, R.R.; Wang, X.; Hu, W.W.; Wang, G.; Chen, Z. Autophagy. 2013, 9,1321-1333.
[26] Yano, S.; Tokumitsu, H.; Soderling, T.R. Nature. 1998, 396, 584-587.
[27] Means, A.R. Mol. Endocrinol. 2008, 22, 2759-2765.
[28] Wayman, G.A.; Lee, Y.S.; Tokumitsu, H.; Silva, A.J.; Soderling, T.R. Neuron. 2008, 59, 914-931.

002C-3通过抑制MMPs和细胞自噬并激活细胞存活相关的钙信号通路保护小鼠脑缺血再灌注损伤

002C-3 protects the brain against ischemia-reperfusion injury by inhibiting autophagy and stimulating CaMKK/CaMKIV/HDAC4 pathways in mice

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 11

编辑推荐

Metrics

本文评价

[1]	郑吴殷晓, 李海平, 罗来春, 胡春玲, 尤朋涛. TOPC通过抑制PI3K/AKT/mTOR通路, 抑制miR-210, Atg7诱导H1975细胞凋亡[J]. 中国药学(英文版), 2023, 32(11): 881-892.
[2]	王圣鑫, 闫向丽, 郑昊圳, 余健烨, 余爱明, 沈晓, 王利胜. 微透析技术结合液质联用的不同剂量黄芪的补阳还五汤在脑缺血损伤大鼠脑药动学研究[J]. 中国药学(英文版), 2020, 29(2): 90-101.
[3]	于快, 李茹一, 朱元军, 刘晓岩, 王银叶. 针对脑缺血再灌注损伤设计的双功能蛋白的脑保护作用优于单功能蛋白[J]. 中国药学(英文版), 2019, 28(11): 760-769.
[4]	庞雨浓, 梁英文, 王玉刚, 雷帆, 袁梽漪, 邢东明, 李俊, 杜力军. 小檗碱通过调节PPARγ启动子甲基化对缺血再灌注脑损伤的作用[J]. 中国药学(英文版), 2018, 27(3): 170-182.
[5]	张烨, 郑丹萍, 水梦洋, 刘晔, 刘晓岩, 王银叶. 新化合物W026B通过抑制炎性细胞因子的产生减轻缺血性脑损伤, 与tPA合用作用增强[J]. 中国药学(英文版), 2018, 27(10): 675-685.
[6]	尹成, 王杰, 徐沛, 颜丙春. 薯蓣皂苷通过降低胶质细胞活化及维持SOD水平减轻脑卒中小鼠的神经损伤[J]. 中国药学(英文版), 2017, 26(9): 684-691.
[7]	赵曜, 张婧莹, 胡英杰, 吴佳栓, 卜英子, 吕万良. 柔红霉素与罗非昔布联合应用增强三阴性乳腺癌的治疗效应与作用机制[J]. 中国药学(英文版), 2016, 25(6): 438-447.
[8]	刘晓岩, 胡振宇, 陈世忠, 王坚成, 王银叶. 口服和厚朴酚对大鼠脑缺血再灌注(I-R)损伤和SHRsp脑卒中的保护作用[J]. 中国药学(英文版), 2016, 25(12): 882-891.
[9]	王喆, 袁霞, 葛泽梅, 冉福香, 吴军, 李润涛, 崔景荣. 新型蛋白酶体抑制剂YSY-01A诱导PC-3M细胞自噬的作用[J]. 中国药学(英文版), 2014, 23(8): 565-571.
[10]	何冰, 陈小夏, 陈一岳. 茶多酚对脑缺血再灌注损伤的保护作用及在体外抗脂质过氧化和清除自由基作用[J]. , 2002, 11(4): 157-161.
[11]	陈小夏, 何冰. 灯盏花素对大鼠脑缺血再灌注引起抗氧化酶活性改变的影响[J]. , 1998, 7(2): 91-93.